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Abstract
Background: Intracholecystic papillary-tubular neoplasms are rare precursor lesions of gallbladder cancer. They
were proposed as a separate pathologic entity in 2012 by Adsay et al. for the unification of a variety of mass-
forming precursor lesions including papillary adenomas, tubulopapillary adenomas, intestinal adenomas, and others.
They are considered homologous to intrapapillary mucinous neoplasms of the pancreas and intrabiliary papillary
neoplasms of the common bile duct. In contrast with the commoner flat-type precursor gallbladder cancer lesions,
they follow a more indolent clinical course and probably different genetic pathways to carcinogenesis. They are
largely uninvestigated with only a handful of studies providing biological and clinical information. Choledochal
cysts are dilation of the common bile duct. Diagnosis is usually established during childhood, and only a minority
of patients are diagnosed at adulthood. They are of major clinical importance as they are known predisposing
factors for biliary carcinogenesis.
Case presentation: The current report describes a patient with a simultaneous diagnosis of choledochal cyst
and intracholecystic papillary-tubular neoplasm. The patient underwent excision of the extrahepatic biliary tree for
a Todani I choledochal cyst, and histological examination of the specimen revealed an intracholecystic papillary-
tubular neoplasm of the gallbladder. Authors describe diagnostic and clinical course of the patient alongside
clinical and biological characteristics of these rare lesions.
Conclusions: To the best of our knowledge, this is the first report of a patient with a simultaneous diagnosis of
choledochal cyst and intracholecystic papillary-tubular neoplasm. Those rare lesions shed light on different forms
of gallbladder cancer carcinogenesis and its relationship with choledochal cysts and cholestasis.
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Background
Precursor lesions of gallbladder cancer separate into
two categories: those exhibiting flat dysplasia and the
mass-forming lesions. The former are commoner and
proceed to carcinogenesis through a metaplasia-
dysplasia cancer pathway [1, 2]. The latter have been
described under a variety of names including papillary
adenomas, tubulopapillary adenomas, intestinal aden-
omas, and others [3]. The World Health Organization
2010 classification distinguishes two categories, the “ad-
enomas” and the “intracystic papillary neoplasms” [4]
but without providing specific diagnostic criteria and
thus allowing significant overlapping. In 2012, Adsay
et al. [5] proposed unification of those lesions under
the category of “intracholecystic papillary-tubular neo-
plasm” (ICPN) identifying common morphological,
immunohistochemical and clinical characteristics. Fur-
thermore, they proposed homology with the more
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extensively described intraductal papillary mucinous
neoplasms (IPMNs) of the pancreas and the recently
described intraductal biliary mucinous neoplasms (IPBNs)
of the bile ducts. They state that those neoplasms follow
an adenoma-carcinoma sequence, different from the
metaplasia-dysplasia-carcinoma sequence, establishing an
alternative model for gallbladder carcinogenesis.
ICPNs are rare neoplasms of the gallbladder, homolo-
gous to pancreatic IPMNs, and the recently described
IPBNs. Adsay et al. [5] define them as tumors composed
of preinvasive neoplastic cells that form clinically detect-
able masses >1.0 cm [5]. This definition unifies a wide
spectrum of previously described neoplastic and preneo-
plastic lesions of the gallbladder including papillary ad-
enomas, tubulopapillary adenomas, intestinal adenomas,
biliary adenomas, transitional adenomas, papillary neo-
plasms, papillary carcinomas, and intracystic papillary
neoplasm. Their definition as a single category derives
from their common clinicopathological, immunopheno-
typic and molecular characteristics, their better progno-
sis, and homology to other papillary neoplasms of the
pancreatobiliary track, including pancreatic IPMNs and
biliary IPBNs [3]. The criterion of 1.0 cm is arbitrary yet
relevant since tumors <1 cm are usually undetectable
preoperatively and almost universally benign [6, 7].
Since their first description in 2012 by Asday et al. [5],
only two series by Isozaki et al. [8] and Bennet et al. [9]
encompassing 23 and seven cases, respectively, and
some case reports have been published [2, 10–13]
(Table 1). Undoubtedly, ICPNs have been described in
older series [14], yet adoption of specific diagnostic
criteria only in 2012 makes their retrospective study very
difficult. In fact, the 2010 World Health Classification
recognizes two generic categories, adenomas and intra-
cystic papillary neoplasms, with a variety of subcat-
egories without providing specific diagnostic criteria and
allowing significant overlapping [4].
ICPNs are considered analogous to IPBNs and to a
lesser extent to IPMNs. This is supported by their
exophytic nature, expression of the same cellular line-
ages, similar clinical behavior, and better survival. Fur-
thermore, ICPNs seem to progress to cancer through an
adenoma-carcinoma sequence rather than the much
commoner metaplasia-dysplasia-carcinoma sequence
[5, 8]. Until today, no molecular studies have revealed
specific genetic pathways. Nevertheless, there are dif-
ferences between ICPNs and IPMNs like expression
of a dominant pancreaticobiliary phenotype and normal
GNAS gene expression [11].
Macroscopically, they are polypoid lesion presenting
large villous/papillary growths with smooth surface
projections. They can be sessile or pedunculated [3].
According to Adsay et al. [5], ICPNs can be of papillary
(43 %), tubular (23 %), or mixed (31 %) configuration
and of biliary (50 %), gastric (36 %), intestinal (11 %), or
oncocytic (9 %) cellular lineage. Biliary type ICPNs com-
monly express MUC1, a marker of biliary differentiation;
gastric type ICPNs express MUC5AC; intestinal type
ICPNs express CK20; and oncocytic type ICPNs express
HepPar. Mixed forms are common. Biliary phenotype
and MUC1 expression are bad prognostic factors,
correlated to progression to carcinoma and worse
prognosis [5, 9].
A more benign clinical behavior than flat type precur-
sor lesions characterizes ICPNs. ICPNs are incidentally
found at only 0.4 % of cholecystectomies. Approximately
6.4 % of gallbladder cancers carry an ICPN component,
indicating that ICPNs can progress to gallbladder cancer.
Stage-matched comparison between typical gallbladder
cancer and invasive ICPNs proved that ICPNs
metastasize less often to lymph nodes and have better
disease-free and overall survival [5, 8, 13]. ICPN
component at invasive cancer usually is of papillary
configuration and has a more extensive component of
high-grade dysplasia, indicating a stepwise progression
to carcinoma [5]. The difference in prognosis can be
attributed to their exophytic nature causing earlier
symptoms and earlier diagnosis or an inherent more
Table 1 Series in the literature describing ICPNs
Author No Patients Size Invasive Subtype T stagea Survival
Noninvasive Invasive
Adsay et al. [5] 2012 123 F/M: 2/1
Mean age: 61 years







1 year: 90 %
3 years: 90 %
5 years: 58 %
1 year: 69 %
3 years: 60 %
5 years: 60 %
Isozaki et al. [8] 2014 23 F/M: 9/14
Mean age: 69 years






3 years: 91 %
5 years: 67 %
Bennet et al. [9] 2015 7 F/M: 6/1
Mean age: 68 years






3 years: 71 %
5 years: 58 %
aApplies only to invasive disease
ICPNs intracholecystic papillary neoplasms
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indolent biology [3, 8, 9, 13]. Notably, similar conclu-
sions have been reached for IPBNs [15].
Choledochal cysts are rare congenital dilatations of the
biliary track. Although benign, their presence is associ-
ated with serious complications including biliary carcin-
oma, pancreatitis, and choledocholithiasis [16]. Their
incidence in the Western population is estimated at 1/
100.00 and Japanese population at 1/1000 [17, 18]. They
are classified into five types according to the Todani
classification: [19] type I: fusiform cystic dilation of the
extrahepatic biliary tree (80 %), type II: bile duct diver-
ticulum, (3 %), type III choledochocele (4 %), type IV:
Multiple extrahepactic bile duct dilatations (13 %), and
type V: Caroli’s disease (1 %) [20].
Choledochal cysts are predominantly present in chil-
dren. They are four times commoner in females. In
developed countries, only 20–30 % of the patients are
diagnosed at adulthood [16]. Patients carry a significant
risk for biliary track cancer, with incidence increasing
with age <1 % in patients younger than 10 years, 15 % in
patients older than 20 years, and up to 35 % in patients
>60 years [18, 21]. Seventy percent of the tumors are
located in the bile ducts and 30 % in the gallbladder
[18]. Excision of the extrahepatic biliary tree with the
creation of a Roux-en-Y hepaticojejunostomy is the best
treatment option for types I and IV. Diverticulotomy
with primary common bile ducts closure is usually suffi-
cient for type II, while type V requires orthotopic liver
transplantation as treatment. All types of choledochal
cyst, especially I and IV are known predisposing factors
for cholangiocarcinoma and to a lesser extent for
gallbladder carcinoma [16, 22].
Etiology of choledochal cysts is unknown. Their patho-
physiology is closely related to the existence of pancre-
atic maljunction, i.e., abnormal junction of the common
biliary duct and pancreatic duct outside the duodenal
wall. It is a rare disorder, occurring in less than 2 % of
the population while >80 % of all pediatric choledochal
cysts are associated with pancreatobiliary maljunction
[16, 23]. Sphincter of Oddi cannot prevent regurgitation
and a premature mixture of bile and pancreatic juice
into the common bile duct or the pancreatic duct, lead-
ing to improper activation of pancreatic enzymes,
deconjugation of bile salts and subsequent cholestasis
and chronic inflammation. Amylase levels at common
bile duct are elevated in patients with pancreatobiliary
maljunction [16]. Pancreatobiliary maljunction is a
known predisposing factor for both cholangiocarcinoma
and gallbladder carcinoma and, to a lesser extent,
pancreatic carcinoma [16, 18, 24, 25].
Case presentation
A young Caucasian female patient aged 28 years came
to our hospital complaining of chronic right upper
quadrant pain. Physical examination was unremarkable
Fig. 2 Intraoperative cholangiography of the patient showing a type
I Todani classification choledochal cyst. Arrow cystic duct, arrowhead
common bile duct, *choledochal cyst
Fig. 1 Preoperative magnetic resonance cholangiopancreatography
showing a type I Todani classification choledochal cyst. Arrow cystic
duct, arrowhead common bile duct, *choledochal cyst
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as was her medical history. She was investigated with
upper abdominal ultrasound that was negative for cho-
lolithiasis but revealed dilated gallbladder and common
bile duct with a diameter of 2.1 cm. Her laboratory
values were within normal limits with total bilirubin of
0.28 mg/dl, alkaline phosphatase (ALP) at 42 U/l, and
γ- GT 16 U/l. Serum tumor markers were within nor-
mal limits. The patient was further studied with com-
puterized tomography, magnetic resonance imaging,
and magnetic resonance cholangiopancreatography
Fig. 3 Macroscopic image of the specimen showing a type I choledochal cyst and a dilated cystic duct
Fig. 4 Histological and immunohistochemical features of the neoplasm. a Prominent intraluminal papillary proliferation of the gallbladder (×20).
b A papillary neoplasm is filling the lumen of the cystic duct (×20). c Pancreatobiliary-type epithelium with mild nuclear pseudostratification
(×100). d MUC1 expression (×200). e MUC5AC expression (×200). f MUC2 negativity (×200)
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(Fig. 1) that proved dilation of common bile duct
between the confluence of hepatic ducts down to the
upper pancreatic border. The intrapancreatic portion
was normal. The investigation was negative for choled-
ocholithiasis and otherwise unremarkable. Pancreatico-
biliary junction was normal.
With a diagnosis of a choledochal cyst, Type Ia ac-
cording to Todani classification, the patient underwent
excision of the extrahepatic biliary tree with Roux-en-Y
reconstruction. An intraoperative cholangiography was
performed for diagnosis confirmation (Fig. 2).
The patient had an uneventful recovery and left the
hospital at the seventh postoperative day. Specimen was
sent for histological examination (Fig. 3). On histology,
the gallbladder, the cystic duct, and partly the com-
mon bile duct showed a prominent intraluminal pap-
illary proliferation of neoplastic epithelial cells with
delicate fibrovascular stalks. Papillary epithelium
consisted of columnar cells with eosinophilic cyto-
plasm and round nuclei with minimal irregularities
and mild pseudostratification, resembling slightly dys-
plastic biliary epithelium. Immunohistochemical stain-
ing revealed MUC1 and MUC5AC expression while
tumor cells were negative for MUC2. Findings were
consistent with intracystic papillary neoplasm of the
gallbladder and intraductal papillary neoplasm of the
cystic and common bile duct with low-grade dyspla-
sia, pancreatobiliary subtype (Fig. 4).
Conclusions
In this report, authors describe a rare case of ICPN
incidentally discovered after excision of the extrahe-
patic biliary tree for a type I choledochal cyst in a
young female patient. We also perform a brief litera-
ture review on ICPNs and mechanisms of gallbladder
carcinogenesis. To the best of our knowledge, this is
the first time an ICPN was reported in a patient with
a choledochal cyst.
Resende et al. [10] reported a simultaneous diagnosis
of an ICPN and an IPBN in the same patient. This
patient also presented pancreaticobiliary maljunction,
a common etiologic factor for both gallbladder cancer
and cholangiocarcinoma. Similarly, Kasuya et al. re-
ported a patient with pancreaticobiliary maljunction
and simultaneous diagnosis of gallbladder cancer and
cholangiocarcinoma [26].
Those rare precancerous lessions give insight to
carcinogenesis of biliary track cancer. Their rarity does
not allow concrete conclusion formulation; still, few
accumulated evidence indicates a relationship between
extrahepatic obstruction and biliary stasis and carcino-
genesis in the biliary track. Biliary stasis causes con-
tinuous inflammation and epithelium damage, leading
the biliary epithelium to regenerative cycles. Inevitable
acceleration of the cell cycle makes it susceptible to
metaplasia and consequent dysplasia. It seems that this
pathophysiological mechanism also causes ICPNs, yet
why some patients will follow the more malignant
metaplasia-dysplasia-carcinoma pathway and others the
more indolent adenoma-carcinoma pathway remains
unknown [1, 27].
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